Live Breaking News & Updates on Patients With Relapsed Refractory Multiple Myeloma

Stay updated with breaking news from Patients with relapsed refractory multiple myeloma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy. ....

New York , United States , Saadz Usmani , Chris Ryan , Live On Air , Myeloma Service , Memorial Sloan Kettering Cancer Center , Onclive On Air , Apple Podcasts , Google Podcasts , Amazon Music , Fda Approval Of Cilta Cel , Patients With Relapsed Refractory Multiple Myeloma ,

Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple Myeloma

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma. ....

United States , Hans Lee , Department Of Lymphoma Myeloma , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Myeloma Clinical Research , Multiple Myeloma Clinical Research , Cancer Medicine , Cancer Center , Linker Mm1 Trial , Patients With Relapsed Refractory Multiple Myeloma ,

Dr Hashmi on Real-World Teclistamab Use in Relapsed/Refractory Multiple Myeloma

Hamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma. ....

Hamza Hashmi , University Of South Carolina Hollings Cancer Center , Medical University , South Carolina Hollings Cancer Center , Efficacy And Safety Of Teclistamab , Patients With Relapsed Refractory Multiple Myeloma , Medical University Of South Carolina Hollings Cancer Center ,

Ultrasensitive BCMA CARs Deliver Responses With Tolerable Safety in R/R Multiple Myeloma

The use of the BCMA-directed CAR T-cell therapy D8 Fab CAR and the dual-targeting AUTO8 CAR T-cell therapy is safe and feasible in patients with relapsed/refractory multiple myeloma. ....

Lydia Lee , University College London , D8 Fab Car , Patients With Relapsed Refractory Multiple Myeloma , Mcarty Trial ,

Ongoing Research Aims to Use Bispecific Antibodies in Earlier Settings and Novel Combinations in Myeloma

Joshua Richter, MD, provides an overview of the current state of bispecific antibodies in multiple myeloma, discusses ongoing investigations of these agents, and expands on their unique toxicities and the need for proactive management. ....

United States , New York , Alfred Garfall , Joshua Richter , Tisch Cancer Institute , Division Of Hematology , University Of Pennsylvania , Medical Oncology , Multiple Myeloma , Blavatnik Family Chelsea Medical Center , Mount Sinai , Patients With Relapsed Refractory Multiple Myeloma , Bispecific Antibodies In Multiple Myeloma , Mount Sinai ,